Glaukos Corporation $GKOS Shares Sold by Brown Capital Management LLC

Brown Capital Management LLC lessened its position in shares of Glaukos Corporation (NYSE:GKOS) by 33.0% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 762,760 shares of the medical instruments supplier’s stock after selling 376,359 shares during the quarter. Glaukos makes up about 2.6% of Brown Capital Management LLC’s holdings, making the stock its 15th largest position. Brown Capital Management LLC owned about 1.33% of Glaukos worth $62,203,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of GKOS. UMB Bank n.a. grew its holdings in Glaukos by 102.6% during the 3rd quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 158 shares during the last quarter. AlphaQuest LLC raised its holdings in Glaukos by 5,754.5% in the 2nd quarter. AlphaQuest LLC now owns 644 shares of the medical instruments supplier’s stock valued at $67,000 after acquiring an additional 633 shares during the last quarter. Smartleaf Asset Management LLC increased its stake in Glaukos by 16.2% in the second quarter. Smartleaf Asset Management LLC now owns 973 shares of the medical instruments supplier’s stock valued at $99,000 after purchasing an additional 136 shares during the last quarter. Parkside Financial Bank & Trust increased its stake in shares of Glaukos by 909.7% during the 2nd quarter. Parkside Financial Bank & Trust now owns 1,252 shares of the medical instruments supplier’s stock valued at $129,000 after acquiring an additional 1,128 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Glaukos by 4,970.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,724 shares of the medical instruments supplier’s stock worth $141,000 after acquiring an additional 1,690 shares during the last quarter. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

GKOS has been the topic of a number of research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Glaukos in a report on Thursday, January 22nd. The Goldman Sachs Group restated a “buy” rating and issued a $138.00 price objective on shares of Glaukos in a report on Friday, January 9th. Stephens increased their target price on shares of Glaukos from $115.00 to $145.00 and gave the stock an “overweight” rating in a research report on Friday, January 2nd. Wells Fargo & Company increased their price objective on shares of Glaukos from $120.00 to $122.00 and gave the stock an “overweight” rating in a research report on Thursday, October 30th. Finally, Needham & Company LLC restated a “buy” rating and set a $125.00 target price on shares of Glaukos in a report on Wednesday, January 14th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $132.54.

Glaukos Price Performance

Shares of NYSE GKOS opened at $117.53 on Tuesday. The company has a current ratio of 5.20, a quick ratio of 4.47 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $6.75 billion, a price-to-earnings ratio of -76.32 and a beta of 0.70. Glaukos Corporation has a twelve month low of $73.16 and a twelve month high of $161.78. The business has a 50 day simple moving average of $113.61 and a 200-day simple moving average of $96.96.

Insider Activity

In other Glaukos news, CFO Alex R. Thurman sold 315 shares of the firm’s stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $105.00, for a total value of $33,075.00. Following the transaction, the chief financial officer owned 50,488 shares of the company’s stock, valued at $5,301,240. This trade represents a 0.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Joseph E. Gilliam sold 10,498 shares of the company’s stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $127.68, for a total value of $1,340,384.64. Following the transaction, the chief operating officer directly owned 92,366 shares of the company’s stock, valued at $11,793,290.88. This trade represents a 10.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 329,655 shares of company stock valued at $37,752,234 over the last quarter. Corporate insiders own 6.40% of the company’s stock.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.